Production (Stage)
Celldex Therapeutics, Inc.
CLDX
$20.34
-$0.92-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -40.85% | -63.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -40.85% | -63.18% | |||
| Cost of Revenue | 12.09% | 3.70% | |||
| Gross Profit | -13.45% | -8.78% | |||
| SG&A Expenses | 5.43% | 2.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.89% | 3.41% | |||
| Operating Income | -11.98% | -7.48% | |||
| Income Before Tax | -14.24% | -11.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.24% | -11.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.24% | -11.80% | |||
| EBIT | -11.98% | -7.48% | |||
| EBITDA | -12.07% | -7.53% | |||
| EPS Basic | -14.19% | -11.69% | |||
| Normalized Basic EPS | -14.18% | -11.71% | |||
| EPS Diluted | -14.19% | -11.69% | |||
| Normalized Diluted EPS | -14.18% | -11.71% | |||
| Average Basic Shares Outstanding | 0.05% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||